Loading
A phase 3 trial of Durvalumab, Tremelimumab, Cisplatin, Gemcitabine and Carboplatin in bladder & urothelial cancer, run by AstraZeneca, active and no longer recruiting.
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer is a phase 3 interventional study registered as NCT03682068 by AstraZeneca, with 1246 participants enrolled, started 2018-09-27 and due to reach its primary completion in 2026-06-01. Interventions recorded: Durvalumab, Tremelimumab, Cisplatin + Gemcitabine and Carboplatin + Gemcitabine.
Shares Tremelimumab, Muscle-invasive and advanced bladder cancer, Durvalumab, Gemcitabine and the tag pipeline.
Shares Tremelimumab, Muscle-invasive and advanced bladder cancer, Durvalumab, AstraZeneca and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, AstraZeneca, Bladder & urothelial cancer and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer, Cisplatin and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer, Cisplatin and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Durvalumab, Gemcitabine, AstraZeneca and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer, Cisplatin and the tag pipeline.
Shares Tremelimumab, Durvalumab, Gemcitabine, AstraZeneca and the tag pipeline.